The vision of the ImmuneAI project is to reveal the patients with the greatest survival benefit by retrieving baseline clinical and biological characteristics of long-term survivors with immunotherapy. In parallel, safety and QoL profiles of the same patients will be defined, by analyzing clinical factors and patient-reported outcome measures at the time of their long-term follow-up.
For the achievement of this goal, ATC will employ Artificial Intelligence (AI) / Machine Learning (ML) techniques to identify the profile of the users, the potential benefit and the status of their QoL.
ImmuneAI is funded by ASCAPE project and aims contribute new algorithms to improve or/and train ASCAPE Open AI infrastructure to detect new types of cancer or medical conditions.
University of Brescia (Italy) and Athens Technology Center (Greece) are the partners of this project.
The project started in March 2022 and will last for 9 months.
